Database / Pharmaceutical impurity
Pharmaceutical impurityPravastatin EP Impurity B (Sodium Salt)
Pravastatin EP Impurity B (Sodium Salt) is listed in the pharmaceutical impurity collection under CAS 722504-46-3. Its represented structure has formula C23H35NaO8 and a calculated molecular weight of 462.51 g/mol.
2D chemical structure
Chemical identity
- Catalog name
- Pravastatin EP Impurity B (Sodium Salt)
- Common name
- Pravastatin EP Impurity B (Sodium Salt)
- Chemical name
- sodium (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-8-[(2S,3R)-3-hydroxy-2-methylbutanoyl]oxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
- CAS
- 722504-46-3
- SMILES
- C[C@H](C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21)[C@@H](C)O.[Na+]
- InChI
- InChI=1S/C23H36O8.Na/c1-12-4-5-15-8-17(26)10-20(31-23(30)13(2)14(3)24)22(15)19(12)7-6-16(25)9-18(27)11-21(28)29;/h4-5,8,12-14,16-20,22,24-27H,6-7,9-11H2,1-3H3,(H,28,29);/q;+1/p-1/t12-,13-,14+,16+,17+,18+,19-,20-,22-;/m0./s1
- InChIKey
- AIKHPBQZWYYTKO-OYKXKHFWSA-M
- Associated API
- Pravastatin
Record ID: Ad96730b78bea
Computed properties
C23H35NaO8 Molecular formula
462.515 g/molMolecular weight
462.223 DaMonoisotopic exact mass
147.35 ŲTopological polar surface area
-2.9195 Calculated LogP (Wildman–Crippen)
110.2042 cm³/molMolar refractivity (Wildman–Crippen)
8 countHydrogen-bond acceptors
4 countHydrogen-bond donors
Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD. The SMILES contains 2 disconnected components. Calculations retain all represented components.
Molecular descriptor profile
Structural feature counts
Element composition
Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.
Radar values and percentile reference
| Descriptor | Value | Percentile |
|---|---|---|
| Molecular weight | 462.515 | 80.67 |
| Calculated LogP (Wildman–Crippen) | -2.9195 | 2.75 |
| Topological polar surface area | 147.35 | 88.78 |
| Hydrogen-bond acceptors | 8 | 87.87 |
| Hydrogen-bond donors | 4 | 89.70 |
| Rotatable bonds (strict) | 10 | 89.42 |
Complete molecular descriptors
| Property | Calculated value | Unit / type |
|---|---|---|
| Molecular formula | C23H35NaO8 | dimensionless |
| Molecular weight | 462.515 | g/mol |
| Monoisotopic exact mass | 462.223 | Da |
| Topological polar surface area | 147.35 | Ų |
| Calculated LogP (Wildman–Crippen) | -2.9195 | dimensionless |
| Molar refractivity (Wildman–Crippen) | 110.2042 | cm³/mol |
| Hydrogen-bond acceptors | 8 | count |
| Hydrogen-bond donors | 4 | count |
| Rotatable bonds (strict) | 10 | count |
| Heavy atoms | 32 | count |
| Heteroatoms | 9 | count |
| Rings | 2 | count |
| Aromatic rings | 0 | count |
| Aliphatic rings | 2 | count |
| Saturated rings | 0 | count |
| Aromatic heterocycles | 0 | count |
| Aliphatic heterocycles | 0 | count |
| Saturated heterocycles | 0 | count |
| Aromatic carbocycles | 0 | count |
| Aliphatic carbocycles | 2 | count |
| Fraction of sp³ carbon atoms | 0.7391 | fraction |
| Formal charge | 0 | e |
| Disconnected components | 2 | count |
| Isotopically specified atoms | 0 | count |
| Potential atom stereocenters | 9 | count |
| Unspecified atom stereocenters | 0 | count |
| Spiro atoms | 0 | count |
| Bridgehead atoms | 0 | count |
| Labute approximate surface area | 211.1983 | Ų |
| Valence electrons | 176 | count |
| Radical electrons | 0 | count |
| Bertz complexity | 691.4839 | index |
| Balaban J | 0 | index |
Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.
Toxicological services and resources for Pravastatin EP Impurity B (Sodium Salt)
Qualification and safety assessment of Pravastatin EP Impurity B (Sodium Salt)
Explore toxicological qualification of Pravastatin EP Impurity B (Sodium Salt) and ICH M7 mutagenic impurity assessment of Pravastatin EP Impurity B (Sodium Salt) for evaluation of this impurity in its pharmaceutical context.
Where data gaps need to be addressed, resources include read-across assessment for Pravastatin EP Impurity B (Sodium Salt) and acceptable intake and limit justification for Pravastatin EP Impurity B (Sodium Salt). The relevant approach depends on the available evidence, exposure and duration of use.
Related Altox services and technical resources
- ICH M7 Mutagenic Impurity Assessment
- Genotoxic Impurity Risk Assessment
- (Q)SAR Mutagenicity Assessment
- Mutagenic and Non-Mutagenic Impurity Assessment
- Toxicological Qualification of Impurities and Degradation Products
- Toxicological Read-Across Assessment
- Impurity Specification Setting and Limit Justification
- Acceptable Intake (AI) Assessment and Limit Derivation
Identity sources and calculation method
Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.
Discuss an assessment for Pravastatin EP Impurity B (Sodium Salt)
Explore Altox services and software through the Altox Pharma-Hub.